Sacklers Net Worth (Updated 2026).
The Sackler family, comprising Arthur, Mortimer, and Raymond Sackler, began their pharmaceutical journey in the mid-20th century. Born into a family of pharmacists in Brooklyn, New York, the brothers learned the ropes of the business from their father, Isaac Sackler, who owned a small pharmacy. After completing their medical degrees and residencies, the siblings went on to establish their own pharmaceutical company, Purdue Frederick, in 1952.
Purdue Frederick’s breakthrough came in the 1990s with the introduction of OxyContin, a powerful painkiller. The drug was marketed as a safer, less addictive alternative to other opioids, thanks to its time-release formula. The Sacklers’ innovative marketing strategies and aggressive promotion of OxyContin made the drug a blockbuster success, transforming Purdue Frederick into a multi-billion dollar enterprise.
Table Of Contents
- Sacklers’ Current Net Worth (as of 2025)
- Career
- Other Ventures
- Assets
- Annual Income
- Frequently Asked Questions about Sacklers
- Frequently Asked Questions: Sacklers Net Worth
- 1. What is the estimated net worth of the Sackler family?
- 2. Who are the Sacklers?
- 3. How did the Sacklers build their wealth?
- 4. What is OxyContin?
- 5. How has the opioid crisis affected the Sacklers’ net worth?
- 6. Have the Sacklers faced any legal consequences related to the opioid crisis?
- 7. What is the Purdue Pharma settlement, and how does it affect the Sacklers’ net worth?
- 8. What is the Sackler family’s involvement in art and philanthropy?
- 9. How has the public’s perception of the Sacklers changed over time?
- 10. What is the current status of Purdue Pharma and the Sacklers?
Sacklers’ Current Net Worth (as of 2025)
The Sackler family, known for their involvement with Purdue Pharma and the opioid crisis, had an estimated net worth of $13 billion as of 2025, according to Forbes. This figure has significantly decreased from its peak due to legal settlements and fines related to the opioid crisis.
Career
The Sackler family’s fortune began with Arthur Sackler, a physician and entrepreneur who founded Purdue Frederick Company in 1952. His brothers, Raymond and Mortimer, later joined the business. Purdue Pharma, the company’s successor, introduced OxyContin in 1996, a highly addictive painkiller that would become the center of the opioid crisis.
Other Ventures
Beyond Purdue Pharma, the Sacklers have diversified their investments. They have interests in real estate, art, and philanthropy. The family has donated significantly to cultural institutions, including the Metropolitan Museum of Art and the Royal Academy of Arts, often using their charitable foundation, the Sackler Trust.
Assets
The Sacklers’ assets include properties in the United States and abroad, such as a 40-acre estate in Connecticut and a penthouse in London. They also own a significant art collection, including works by Picasso and Matisse. The family’s philanthropic giving is often tied to their art collection, with many pieces donated to museums.
Annual Income
The Sacklers’ annual income is not publicly disclosed. However, it’s estimated to be in the hundreds of millions of dollars, primarily from Purdue Pharma and other investments. The company’s revenue from OxyContin alone was over $35 billion between 1996 and 2016. Despite the company’s role in the opioid crisis, the Sacklers have maintained their wealth and influence.
Frequently Asked Questions about Sacklers
Frequently Asked Questions: Sacklers Net Worth
1. What is the estimated net worth of the Sackler family?
The latest estimated net worth of the Sackler family is approximately $13 billion.
2. Who are the Sacklers?
The Sacklers are a family known for their involvement in the pharmaceutical industry, particularly through Purdue Pharma, the company that developed and marketed OxyContin.
3. How did the Sacklers build their wealth?
The Sacklers’ wealth primarily comes from their ownership of Purdue Pharma, which they inherited from their father, Raymond Sackler, and his brothers, Mortimer and Arthur.
4. What is OxyContin?
OxyContin is a powerful opioid painkiller developed and marketed by Purdue Pharma. It was first approved by the FDA in 1995 and has since become one of the most prescribed and controversial medications in the United States.
5. How has the opioid crisis affected the Sacklers’ net worth?
The opioid crisis, in which Purdue Pharma and the Sacklers have been heavily involved, has led to numerous lawsuits and fines. While the exact impact on their net worth is not clear, it is believed to have significantly decreased their wealth.
Yes, several members of the Sackler family have faced legal consequences related to the opioid crisis. In 2020, Purdue Pharma pleaded guilty to criminal charges, and members of the Sackler family were personally named in several lawsuits.
7. What is the Purdue Pharma settlement, and how does it affect the Sacklers’ net worth?
The Purdue Pharma settlement, announced in 2020, includes a $3.54 billion criminal penalty and $2.8 billion in damages. The Sacklers are expected to pay a significant portion of this settlement, which will likely further decrease their net worth.
8. What is the Sackler family’s involvement in art and philanthropy?
The Sackler family is known for its involvement in art and philanthropy. They have donated to various museums and cultural institutions, with the Sackler Wing at the Metropolitan Museum of Art in New York being one of the most notable examples.
9. How has the public’s perception of the Sacklers changed over time?
The public’s perception of the Sacklers has significantly shifted over time, particularly in relation to the opioid crisis. While they were once praised for their philanthropy and business acumen, they are now widely criticized for their role in the crisis and their handling of Purdue Pharma.
10. What is the current status of Purdue Pharma and the Sacklers?
Purdue Pharma has filed for bankruptcy as part of the settlement agreement, and the Sacklers have stepped down from their roles within the company. The future of both Purdue Pharma and the Sacklers’ involvement in the pharmaceutical industry remains uncertain.
